News

Accountable care organizations in the Medicare Shared Savings Program generated $1.19 billion in total net savings to Medicare in 2019, the third and largest annual savings for the program to date, Centers for Medicare & Medicaid Services Administrator Seema Verma announced.

The Centers for Medicare & Medicaid Services released guidance for states on opportunities to advance value-based care in Medicaid, which reviews available federal authorities and “lessons learned” from early state and federal experiences.

The Centers for Medicare & Medicaid Services proposes to fully phase in its new risk adjustment model for Medicare Advantage plans in calendar year 2022, as required by the 21st Century Cures Act, the agency announced yesterday.

As urged by the AHA, the Centers for Medicare & Medicaid Services announced that it will withdraw its Medicaid fiscal accountability proposed rule from its regulatory agenda.

A Centers for Disease Control and Prevention study found that Hispanic, Black and American Indian/Alaskan Native persons under the age 21 disproportionately accounted for most COVID-19-related deaths in this age category.

People recently diagnosed with substance use disorders were more likely to develop COVID-19 and be hospitalized or die from the virus, according to a National Institutes of Health-funded study.

A bipartisan group of lawmakers in the House of Representatives are mobilizing around a new COVID-19 relief proposal.

As part of AHA’s We Care, We Vote initiative the association released a new video featuring current and former members of the AHA Board of Trustees discussing the importance of voting and sharing how they encourage voter participation at their organizations.

As urged by the AHA, the Centers for Medicare & Medicaid Services (CMS) announced that it will withdraw its Medicaid fiscal accountability proposed rule from its regulatory agenda.

The Institute for Healthcare Improvement’s National Steering Committee for Patient Safety, whose members include the AHA and its American Organization for Nursing Leadership, released a national action plan to accelerate patient safety progress across the care continuum.

President Trump issued a new executive order that seeks to lower prescription drug prices. The order directs the Secretary of Health and Human Services to test a “most-favored-nation” pricing model for Part B, and some Part D, drugs.

A new study demonstrates the cost to the U.S. health care system from an anti-competitive tactic known as “product hopping,” which involves a brand name drug company moving patients to a new reformulated version of a drug when an existing drug’s exclusivity is close to expiring.

The Oregon Association of Hospitals Research & Education Foundation has established a relief fund to support hospital workers affected by the state’s wildfires, as well as future disasters.

To ease the continued strain on the N95 supply chain and Strategic National Stockpile, the National Institute for Occupational Safety and Health is considering whether the federal government should buy and deploy elastomeric half-mask respirators in health care settings and emergency medical services organizations during the COVID-19 crisis.

The Department of Labor released a temporary rule revising regulations implementing certain paid leave provisions through Dec. 31 under the Families First Coronavirus Response Act.

Flu season soon will be upon us. And this year, it will take place in the middle of our ongoing battle against COVID-19.

The AHA and Aligning for Health Sept. 24 at 3 p.m. ET will host a webinar detailing how hospitals and health systems have been working to better identify and address health, social and community needs.

A new Centers for Disease Control and Prevention study is revealing the extent to which adults are bypassing medical care because of their COVID-19-related concerns.

A Centers for Disease Control and Prevention study revealed that adults with positive SARS-CoV-2 test results were approximately twice as likely to have reported dining at restaurants within 14 days of developing symptoms compared with those whose test results were negative.

The National Institutes of Health announced the launch of two of three planned, worldwide phase 3 clinical trials of varying types of blood thinners to treat adults with COVID-19.